Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lactobacillus plantarum A87
- Development stage
- Unknown
- Lead developer
- Athelas B&P
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
*Lactobacillus plantarum* A87 is a specific probiotic bacterial strain belonging to the species *Lactiplantibacillus plantarum* (formerly *Lactobacillus plantarum*). It is primarily developed and investigated for its metabolic health benefits, particularly in the management of obesity and related metabolic disorders. The strain exerts its therapeutic effects through the modulation of the gut microbiota and the regulation of host lipid metabolism. Research indicates that A87 can suppress the expression of key adipogenic transcription factors, including peroxisome proliferator-activated receptor gamma (PPAR-gamma) and CCAAT/enhancer-binding protein alpha (C/EBP-alpha), thereby inhibiting adipocyte differentiation and fat accumulation. Additionally, it has been observed to reduce systemic inflammation and improve glucose tolerance in preclinical models and human clinical trials. It is typically commercialized as a functional food ingredient or a dietary supplement for weight management.
- Brand names
- A87 ProbioticsA-87 ProbioticsA 87 Probiotics
- Other names
- Lactiplantibacillus plantarum A87L. plantarum A87
02
Targets
PPARG (Peroxisome proliferator-activated receptor gamma)CEBPA (CCAAT enhancer-binding protein alpha)
Beyond the preview
Go deeper on Lactobacillus plantarum A87.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lactobacillus plantarum A87.